12 Sep 2018 11:40
Â
Â
AIM: RENE | 12 September 2018 |
Â
ReNeuron Group plc
("ReNeuron" or the "Company")
Â
Result of AGM
Â
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting, held earlier today, were duly passed.
Â
Â
ENDS
Â
Enquiries:
Â
ReNeuron | +44 (0) 20 3819 8400 |
Olav Hellebø, Chief Executive Officer | |
Michael Hunt, Chief Financial Officer | |
 Buchanan |  +44 (0) 20 7466 5000 |
Mark Court, Sophie Wills, Tilly Abraham | |
Stifel Nicolaus Europe Limited Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) | +44 (0) 20 7710 7600 |
N+1 Singer Advisory LLP Mark Taylor (Joint Broker) | Â +44 (0) 20 7496 3000 |
About ReNeuron
Â
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
Â
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.
Â
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
Â
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
Â
Â